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Introduction
Multiple sclerosis (MS) is a chronic progressive disease 
of the central nervous system (CNS) that mostly affects 
young adults. Histopathologically, the disease consists 
of multifocal areas of demyelination and axonal loss in 
white (WM) and gray matter (GM) throughout the 
CNS.1
MS clinical features are heterogeneous and change 
over time, leading to a significant and irreversible disa-
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Abstract
Objective: The objective of this paper is to identify clinical or magnetic resonance imaging (MRI) predictors of long-
term clinical progression in a large cohort of multiple sclerosis (MS) patients.
Methods: A total of 241 relapsing–remitting (RR) MS patients were included in a nine-year follow-up (FU) study. The 
reference MRIs were acquired at baseline (BL) as part of a multicenter, cross-sectional, clinical-MRI study. Volumetric 
MRI metrics were measured by a fully automated, operator-independent, multi-parametric segmentation method. Clinical 
progression was evaluated as defined by: conversion from RR to secondary progressive (SP) disease course; progression 
of Expanded Disability Status Scale (EDSS); achievement and time to reach EDSS 4.
Results: We concluded that conversion from RR to SP (OR 0.79; CI 0.7–0.9), progression of EDSS (OR 0.85; CI 0.77–
0.93), achievement of EDSS 4 (OR 0.8; CI 0.7–0.9), and time to reach EDSS 4 (HR 0.88; CI 0.82–0.94) were all predicted 
by BL gray matter (GM) volume and, except for progression of EDSS, by BL EDSS (respectively: (OR 2.88; CI 1.9–4.36), 
(OR 2.7; CI 1.7–4.2), (HR 3.86; CI 1.94–7.70)).
Conclusions: BL GM volume and EDSS are the best long-term predictors of disease progression in RRMS patients with 
a relatively long and mild disease.
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bility in about 50% of patients after a median time of 8.6 
years.2,3 To assess disability, among several clinical rat-
ing scales, the Expanded Disability Status Scale (EDSS) 
is the most widely used in clinical practice and clinical 
trials.4
The prognosis is highly variable and unpredictable.5–7 A 
subset of patients shows a benign disease course with only 
a few relapses and none or only minimal disability 15 years 
after disease onset.8 On the other side, rapidly progressing 
disability may lead to some patients needing wheelchairs 
within a few years from the disease onset.9
At the present time, there is a definite need for a single 
or combined objective marker to reliably predict long-term 
disease evolution, and consequently to optimize patients’ 
management. Many demographic and clinical markers 
have been tested in MS, yielding significant results.10,11 
Objective magnetic resonance imaging (MRI)-derived 
markers have also been tested, showing great potential.12–19 
Nevertheless, most of the MRI studies conducted so far 
have been weakened by methodological limitations such as 
monocentric design,13,15–17,19 small sample size13,15–17,19 and 
length of follow-up (FU).15,17
In previous studies,15,17–19 including our previous mul-
ticenter, clinical-MRI cross-sectional study20, in which a 
very large cohort of MS patients underwent the same MRI 
protocol on the same mobile scanner and with centralized 
data analysis, the important role of GM volume in deter-
mining disability has already been highlighted. The pre-
dictive value of MRI parameters, including GM volume, 
has been assessed in few longitudinal21,22 studies with 
adequate sample size and follow-up duration. Therefore, 
taking advantage of the availability of data coming from 
our previously mentioned cross-sectional study, we aimed 
at identifying which baseline (BL) MRI or combined clin-
ical/MRI measure was the best predictor of long-term 
clinical progression.
Methods
Patients and clinical data
Of the initial cohort of 597 MS patients participating to the 
previous multicenter clinical-MRI research,20 303 subjects 
(50.7%; female (F)/male (M) 202/101; median age 45 
years; median age at disease onset 26 years) were enrolled 
in this nine-year FU study. The number of patients lost at 
FU was considerable (294; 49.4%), and the reasons were: 
missing contact information (50.7%), unavailability 
(24.1%), refusal (20.1%), death (3.4%), and other major 
medical illnesses (1.7%). However, there were no signifi-
cant differences in BL demographic or clinical data between 
patients lost at FU and those participating in the initial 
cross-sectional study, except for a minor percentage of 
relapsing–remitting (RR) patients in the dropped-out popu-
lation (65% RR patients in the dropped-out group, 72.4% in 
the FU group; p < 0.02). At BL, disease course was RR in 
241/303 (79.5%) patients, secondary progressive (SP) in 
47/303 (15.5%) and primary progressive (PP) in 15/303 
(5%). Because of the purpose of the study, progressive 
patients at BL (both PP and SP) were excluded from statis-
tical analysis that focused only on RR patients, being the 
only group suitable to assess all the predefined criteria of 
disease progression. During FU clinical evaluations were 
performed at BL and at three six-month intervals or on the 
occasion of relapse at the same reference MS center. The 
reference MRI was acquired at BL. Mean FU was 109.3 ± 
7.5 months. Clinical data consisted of age at BL, age at first 
clinical episode (disease onset), disease duration (DD) at 
BL and at FU, disease course and disability at BL and dur-
ing FU (as measured by EDSS score), annualized relapse 
rate (ARR) during FU and use of disease-modifying treat-
ments (DMT) at BL and FU. All participants gave written 
informed consent and the protocol was approved by local 
ethic committees.
Mri
At BL, all MS subjects underwent the same imaging proto-
col as described in the previous cross-sectional study (see 
Appendix).20 All the studies were segmented using a multi-
spectral fully automated method (see Appendix), based on 
relaxometric characterization of brain tissues.23,24
The software furnished complete sets of multi-feature 
images (R1(=1/T1), R2(=1/T2), proton density (N(H))-
based) and segmented images, and calculated the vol-
umes of the following intracranial tissues: cerebrospinal 
fluid (CSF), GM, WM and abnormal white matter 
(AWM). To normalize for head size variability, the vol-
umes of intracranial tissues were expressed as fractions 
(f) of the intracranial volume, which were calculated for 
each subject as the sum of all intracranial tissues. AWM-f 
is a measure of lesion load as determined by the R1, R2 
and N (H) information and morphological characteristics, 
the reduction of WM-f indicates WM volume reduction, 
the reduction of GM-f indicates reduction of GM volume, 
and the increase in CSF-f indicates global brain volume 
reduction.
Definition of disease progression
To identify long-term clinical and MRI predictors of MS 
evolution, we defined disease progression as follows:
1) Conversion from RR to SP disease course;
2) Progression of EDSS, considered as a one-point 
increase for EDSS ≤ 5.5 and a 0.5-point increase 
(confirmed after at least three months) for EDSS > 
5.5;25
3) Achievement of milestone EDSS 4;
4) Time to reach milestone EDSS 4.
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Statistical analysis
MRI volume data were presented as means and 95% confi-
dence interval (CI). The mean MRI parameters of all sub-
jects were adjusted by age, gender and education using a 
linear regression model. Before regression analysis, indi-
vidual variables were checked for skewness and the pres-
ence of outliers.
Because of the high inter-correlation of MRI variables 
(generating multicollinearity), the less statistically corre-
lated measures (AWM-f, GM-f and CSF-f), still represent-
ing the main aspect of MS pathology, were included in the 
multivariate model. Statistical analysis was performed 
using STATA 12.0, and a p value < 0.05 was considered 
statistically significant. Shapiro Wilk test was used to eval-
uate normality assumption; in case of violation of normal-
ity distribution, median and interquartile range were used. 
Kruskall Wallis test and Chi square test were used to com-
pare the two groups (BL RR who remained RR at FU 
(RR→RR), and RR patients who converted to SP course 
(RR→SP) during FU), respectively, for quantitative and 
qualitative data. Mann-Whitney U test was used to com-
pare BL data of RR→SP to RR→RR patients and to com-
pare patients who reached EDSS 4 and patients who did 
not. Variance inflation factor (VIF) was calculated to evalu-
ate multicollinearity problems of MRI variables in the mul-
tivariate regression. Variables correlating with outcomes (p 
< 0.1) in univariate analysis were used as independent vari-
ables in multivariate logistic regression. Data log transfor-
mation of the ARR variable was used in multivariate 
logistic regression because it was not normally distributed, 
and regression residual study confirmed that the log trans-
formation was more appropriate for statistical analysis. 
Three logistic regression stepwise analyses were performed 
with p = 0.10 as the critical value for entering or excluding 
variables in the model. In the first one, conversion RR→SP 
was considered as a dependent variable, (independent vari-
ables: age, BL EDSS, DD, AWM-f, CSF-f, GM-f): Only 
GM-f and EDSS remained in the final model. In the second 
model, EDSS progression (considered as a one-point 
increase for at least three months for EDSS ≤ 5.5 and a 0.5-
point increase for at least three months for EDSS > 5.5) was 
considered as a dependent variable (independent variables: 
BL EDSS, GM-f, age, age at onset and DD): Only GM-f 
remained in the final model. In the third model, the achieve-
ment of EDSS 4 was used as a dependent variable (inde-
pendent variables: age, BL EDSS, AWM-f, CSF-f, GM-f, 
DD): Only GM-f and EDSS remained in the final model.
In the third model patients with EDSS ≥ 4 who did not 
stay stable at EDSS 4 were excluded from the analysis. 
Odds ratio (OR) and their 95% CIs were calculated. 
Survival analysis was made to evaluate time to reach the 
milestone EDSS 4. Kaplan-Meier curve of RR→RR and 
RR→SP patients were compared using the log-rank test. In 
addition, a Cox proportional hazard model was calculated 
to estimate the hazard ratio (HR) and their 95% CIs. The 
included independent variables were those with p < 0.1 in 
the univariate model. A stepwise model was used with p = 
0.10 as the critical value for entering or excluding variables 
in the model. The EDSS variable did not respect assump-
tion of hazard proportion overtime and for this reason was 
in the model as time depending.
Results
Descriptive analysis of demographic, clinical and BL MRI 
data of the investigated cohort, divided by clinical pheno-
type, is shown in Table 1.
The clinical/demographic and BL MRI characteristics of 
RR patients are shown in Table 2. Of the 241 RR patients, 
199 (82.6%) remained RR (RR→RR), while 42 (17.4%) 
progressed to the SP course during FU (RR→SP).
ARR was available for 238/241 RR patients: The uni-
variate analysis showed that the raw data of ARR had a 
negative correlation with age at disease onset (r = −0.22; p 
< .001), age at BL (r = −0.22; p < .001) and a positive cor-
relation (r = 0.19; p < .003) with GM-f. The multivariate 
analysis on the log transformation of ARR showed only a 
significant correlation with age at disease onset (coef = 
–.02; t = −3.25; p < 0.001; CI –.033 to .008). No correla-
tions were found between ARR and conversion from RR to 
Table 1. Clinical, demographic and adjusteda BL MRI volumes (as percentage of whole-brain volume) of 241 RRMS patients 
followed up for nine years.
Age at FU 
(mean ± 
SD; median, 
range)
Age at on-
set (mean ± 
SD; median, 
range)
BL EDSS 
(mean ± 
SD; median, 
range)
DD at BL 
(years) (mean 
± SD; median, 
range)
DD at FU 
(years) (mean 
± SD; median, 
range)
AWM-f 
(mean ± 
SD; median, 
range)
CSF-f (mean 
± SD; median, 
range)
GM-f (mean 
± SD; median, 
range)
RR→RR 43.8 ± 8.9 27.2 ± 7.9 2.1 ± 0.9 7.8 ± 6.0 16.9 ± 6.0 1.0 ± 1.3 14.2 ± 4.1 51.9 ± 2.8
(n = 199) 43.0, 25–68 26.0, 14–53 2.0, 0–5 6.0, 1–37 15.0, 10–36 0.6, 0–9.2 13.9, 5.8–28.3 52.1, 42.3–58.2
RR→SP 47.3 ± 9.8 28.0 ± 8.8 3.17 ± 1.0 10.2 ± 7.5 19.3 ± 8.0 2.1 ± 2.5 18.0 ± 5.8 49.4 ± 3.6
(n = 42) 46.5, 20–67 26.0, 15–48 3.5, 1–6 7.0, 1–35 16.0, 10–44 1.4, 0–9.6 17, 8.9–33.4 49.8, 39–57.6
BL: baseline; MRI: magnetic resonance imaging; RRMS: relapsing–remitting multiple sclerosis; SP: secondary progressive; SD: standard deviation; FU: 
follow-up; AWM-f: abnormal white matter fraction; CSF-f: cerebrospinal fluid fraction; GM-f: gray matter fraction; EDSS: Expanded Disability Status 
Scale; DD: disease duration. aAdjusted for age, gender and education.
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SP and progression on the EDSS scale, while ARR was sig-
nificantly higher in patients reaching EDSS 4 (0.33) than in 
patients who did not reach this outcome (0.22) (p < 0.001).
Median EDSS was 2.0 at BL and 3.0 at the end of FU (p 
< 0.001).
At BL therapy was β-interferon in 57.8%, glatiramer 
acetate in 4.6% and immunosuppressants in 5.6%; 32% 
patients were not under treatment.
At FU visit, 47.8% patients were treated with 
β-interferon, 11.5% with glatiramer acetate, 5.9% with 
natalizumab, 6.3% with other immunosuppressant drugs, 
0.4% with fingolimod and 28% were not under treatment.
To evaluate the correlations between the complex treat-
ment scenario and disease progression, we divided the 
whole population of RR patients into four subgroups 
according to the number of treatments during FU (none, 
one, two and > 2). The stepwise logistic regression showed 
that patients treated with > 2 drugs during FU had a signifi-
cantly higher risk of progression compared to the not 
treated patients (respectively: RR → SP (OR 13.8; z = 2.34; 
CI 1.52–125.30); progression of EDSS (OR 4.96; z = 3.03; 
CI 1.76–13.99); achievement of the milestone EDSS 4 (OR 
45.10; z = 3.31; CI 4.72–430.36).
Conversion from RR to SP disease course
Table 2 (right side, left columns) shows group differences 
between RR→RR and RR→SP.
The BL comparison of RR→SP to RR→RR patients 
showed for the second group: i) younger age (34 vs 38 
years; p = 0.021); ii) lower EDSS (2 vs 3.3; p < 0.001 ), 
CSF-f (13.9 vs 17.1; p < 0.001) and AWM-f (0.6 vs 1.4; p = 
0.002); iii) higher GM-f (52.1 vs 49.8 p < 0.001) and WM-f 
(33.2 vs 32.4; p = 0.02). The stepwise logistic regression 
for disease evolution at FU (RR→RR and RR→SP) showed 
an inverse correlation between GM-f and conversion 
RR→SP (OR .79; z = −3.49; CI 0.7–0.9), and a positive 
correlation between EDSS and conversion RR→SP (OR 
2.88; z = 5.02; CI 1.9–4.36). In other words, for a 1% reduc-
tion of GM-f (i.e. 1% decrease of GM volume fraction) at 
BL there was a 20% increased probability of RR patients 
converting to SP, and for each one-point increase on the 
EDSS at BL there was a threefold increased probability of 
conversion to SP.
Progression of EDSS
The multivariate analysis for EDSS progression at FU, con-
sidering the binomial variable “worsening yes/no,” showed 
an inverse correlation between GM-f (OR 0.85; z = −3.47; 
CI 0.77–0.93) and EDSS progression such that a 1% reduc-
tion of GM-f at BL determined a 15% increased probability 
of disease progression.
Achievement of the milestone EDSS 4
Table 2 (right side, right columns) shows the group differ-
ences between RR patients reaching/not reaching the mile-
stone EDSS 4.
At BL 222 patients had an EDSS < 4. During FU 73 
patients (32.8%) reached EDSS 4, while 135 patients 
(61%) did not, and 14 patients (6.3%) reached EDSS ≥ 4 
but did not stay stable on this score and were not included 
in the analysis. The univariate analysis showed that 
patients who reached the milestone during FU, compared 
to patients who did not, had: i) older age at BL (37 vs 33 
years; p = .003); ii) higher AWM-f (1.2 vs 0.6; p = .005) 
and CSF-f (16 vs 13.7; p < .001); iii) higher EDSS (2.5 vs 
2.0; p < .001) and DD (8 vs 6 years; p < .001); and iv) 
lower GM-f (50.3 vs 52.4; p < .001). The multivariate 
analysis regarding the achievement of EDSS 4 showed a 
significant inverse correlation with GM-f (OR 0.8; Z = 
−3.52; CI 0.7–0.9) and a positive correlation with EDSS 
(OR 2.7; z = 4.21; CI 1.7–4.2).
Table 2. Demographic, clinical and adjusteda BL MRI volumes (as percentage of whole-brain volume) of 241 RRMS patients, and of 
the four subgroups: RR→RR, RR→SP, EDSS < 4 and EDSS > 4.
Mean (range) SD Median RR→RR n = 199 RR→SP n = 42 EDSS < 4  
n = 135
EDSS > 4 n = 73
 Median IQ ranges Median IQ ranges p Median IQ ranges Median IQ ranges p
RR n = 241
Age at FU 44.4 (22–77) 9.1 44 34 28–40 38 30–47 0.021 33 27–39 37 31–44 0.003
Age at onset 27.3 (13–54) 8 26 26 21–33 26 21–35 0.755 25 21–31 26 22–34 0.424
AWM-f 1.2 (0–9.61) 1.6 0.6 0.6 0.2–1.4 1.4 0.3–2.6 0.002 0.6 0.1–1.2 1.2 0.3–2.1 0.005
CSF-f 14.9 (5.8–33.4) 4.7 14.4 13.9 11.2–16.4 17.1 13.3–20.9 < 0.001 13.7 10.9–16.2 16.0 13.6–20.0 < 0.001
GM-f 51.4 (39–58.2) 3.1 51.7 52.1 49.9–53.7 49.8 47.7–51.9 < 0.001 52.4 50.5–54.5 50.3 48.3–52.2 < 0.001
BL EDSS 2.3 (0–4.5) 1 2 2 1.5–2.5 3.3 2.5–3.5 < 0.001 2 1.5–2 2.7 2–3 < 0.001
DD at BL 8.5 (1–35) 6.5 7 6 3–11 7 5–15 0.0613 6 3–10 8 5–16 < 0.001
DD at FU (years) 17.4 (10–44) 6.4 15 15 12–20 16 14–24 0.1021 15 12–19 17 13–22 < 0.001
BL: baseline; MRI: magnetic resonance imaging; RR: relapsing–remitting multiple sclerosis; SP: secondary progressive; SD: standard deviation; FU: follow-
up; AWM-f: abnormal white matter fraction; CSF-f: cerebrospinal fluid fraction; GM-f: gray matter fraction; EDSS: Expanded Disability Status Scale; DD: 
disease duration; IQ: interquartile. aAdjusted for age, gender and education.
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Time to reach the milestone EDSS 4
Survival analysis (Figure 1) showed that the median time to 
reach EDSS 4 was 60 months (minimum two months, max-
imum 108 months) with a one-point increase on the EDSS 
in three years in all 73 patients who reached the milestone; 
while considering only patients with a RR→SP course the 
increase was faster (one-point increase on the EDSS in two 
years). Furthermore, there was a different percentage of 
patients who reached EDSS 4 in the two groups: 25% in the 
RR→RR group and 95% in the RR→SP one. The multi-
variate analysis (dependent variable: time to reach EDSS 4; 
independent variables: age, AWM-f, CSF-f, GM-f, BL 
EDSS and DD) showed that the risk of reaching EDSS 4 
was inversely correlated to GM-f (HR 0.88, z = −3.49; CI 
0.82–0.94) and positively correlated to BL EDSS (HR 3.86; 
z = 3.85; CI 1.94–7.70).
Discussion
In long-term FU studies several clinical predictors have 
been identified. In patients with a relapsing onset, higher 
age at disease onset, male gender, short interval between 
first and second relapse, high frequency of relapses, and 
disability at two or five years after onset, all were reported 
to be unfavorable predictors of long-term disease evolu-
tion.5–7,9 In terms of MRI metrics, several cross-sectional 
and longitudinal MRI studies have reported that T2 lesion 
load (LL) behaves as a moderate predictor of long-term dis-
ability.16,26,27 Contrariwise, T1LL, which is more difficult to 
standardize between different MRI raters and centers, cor-
relates with disability more than T2LL.16,28
Most of the longitudinal MRI studies conducted so far, 
focused mainly on early MS, showed that the best predic-
tors of disease progression are the number of gadolinium-
enhancing lesions and the rate of GM atrophy over the first 
years of disease.12,17,21,27,29 Our large cohort of MS patients, 
not in the early phase of the disease and having a relatively 
low disability, is highly representative of a common MS 
outpatient population; in such a context, we aimed at 
assessing the predictive values of BL clinical data and sin-
gle BL MRI examination.
None of the MRI parameters at BL showed to be predic-
tive of the ARR at FU. On the other hand, in the univariate 
analysis ARR was positively correlated to GM-f; it may be 
hypothesized that patients with a more inflammatory dis-
ease may also have GM inflammation/edema as suggested 
by the higher GM volume.
Conversion to SP course, progression of EDSS and 
achievement and time to reach the milestone of EDSS 4 
were all directly correlated to BL GM volume and (except 
for EDSS progression) to BL EDSS. Moreover, the mile-
stone EDSS 4 was reached faster in RR patients who con-
verted to SP.
Altogether these data indicate that EDSS and GM vol-
ume, respectively as clinical and paraclinical parameters, 
are the best predictors of disease progression when consid-
ering a general outpatient MS population. The fact that GM 
volume was the best predictor of disability highlights the 
relevance of selective neurodegenerative markers over 
more traditional WM inflammatory markers (such as T2LL) 
in predicting long-term disability.
The present findings consolidate and extend the obser-
vation made in previous studies that GM involvement cor-
relates more strongly with measurement of physical 
disability than WM damage.20,30,31 Nevertheless, only a few 
long-term FU studies reported specifically on the predictive 
value of GM volume or damage on disability progres-
sion.18,19
The absence of a significant predictive value for the 
AWM-f in our MS population is in contrast with previous 
studies in which LL accrual showed a high predictive value 
in the first years after presentation,12 while it is in agree-
ment with other studies on MS patients with longer DD 
(more similar to our patients) showing that LL was less pre-
dictive of long-term disability.14,32
In the present study, BL EDSS was positively correlated 
to the risk of conversion from RR to SP as well as to the 
achievement and time to reach EDSS 4. These results are in 
agreement with a previous report9 in which patients with a 
BL EDSS < 3 remained fully ambulatory after 10 years in 
contrast to patients with EDSS 3 through 5 who developed 
important gait limitations, with half of them requiring a 
cane over the 10-year period. In another eight-year FU of 
RR patients,33 BL EDSS score was one of the significant 
clinical predictors of future disability.
Altogether our findings suggest that GM volume frac-
tion is the best paraclinical predictor of disability, there-
fore measures of GM volume fraction will be the most 
Figure 1. Kaplan-Meier survival analysis: Time to reach EDSS 4.
Kaplan-Meier survival analysis showing the median time to reach EDSS 
4 in all patients and in the two groups (RR → RR and RR → SP) at 60 
months and at the end of follow-up.
RR: relapsing–remitting multiple sclerosis. RR → RR: patients who re-
mained relapsing–remitting. RR → SP: patients who converted from RR 
to secondary progressive multiple sclerosis. EDSS: Expanded Disability 
Status Scale.
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appropriate to evaluate neuroprotective agents in MS clin-
ical trials.
When considering the value of the present findings, it is 
important to take into account a few limitations: i) the high 
proportion of patients lost at FU. However, as seen in other 
long-term FU studies,16,18,33 the loss of more than 50% of 
patients is quite common; furthermore, in our study the 
absence of significant differences between the original cohort 
and the FU MS population attenuates this criticality; ii) the 
multicenter design of the study and the long-term FU might 
have negatively affected reliability of EDSS scoring and, 
therefore, the evaluation of disease progression. Notably, all 
the evaluating neurologists involved in the study were accus-
tomed to participating in international clinical trials requiring 
EDSS neurostatus certification; iii) the use of two-dimen-
sional instead of three-dimensional sequences acquired on a 
1 Tesla MRI machine; iv) the use of the EDSS in assessing 
long-term progression of MS is less reliable at lower values 
(1.0 to 3.5), when interrater agreement is 70% within one 
EDSS point, compared with an interrater agreement of 80% 
within 0.5 EDSS point at higher EDSS scores (4.0 to 7.0).34,35 
In addition, the EDSS is heavily weighted toward physical 
disability while MS-related cognitive deficits are largely 
underestimated. Nevertheless, EDSS is without doubt the 
most widely accepted measure in MS natural history as well 
as clinical trial studies; iv) the lack of data on cognitive 
impairment; vi) the lack of a thorough examination on 
patients’ treatment; v) the study design was retrospective, 
although enrolled patients were only those regularly fol-
lowed at each MS center; vii) spinal cord atrophy, regional 
LL and cortical lesions could not be evaluated since available 
BL MRI data did not allow such measurements; vi) no post-
contrast images were acquired; however, considering the 
relatively long DD in our MS cohort, this could be consid-
ered a minor caveat. It also has to be considered that the 
results could be affected by the choice of segmentation 
method; in the present study we used the MRI data acquired 
in the previous cross-sectional study, where the need for a 
fully automated procedure derived from the very large num-
ber of MRIs (about 700) to be evaluated.
On the other hand, we believe that the present study 
takes its advantages from the following relevant issues: i) 
the long FU; ii) the large cohort studied, representative of 
the general MS outpatient population; and iii) the applica-
tion of the same MRI protocol to all patients together with 
a centralized MRI data analysis.
In conclusion, the present study clearly shows that BL 
GM volume and EDSS are the best predictors of long-term 
disease progression in RRMS patients with a relatively 
long and mild disease. It also confirms the limited contribu-
tion of WM damage to long-term disability in MS.
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